Darolutamide Alone and in Combination With Goserelin in Androgen Receptor-Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial.
J Clin OncolAug 3, 2026 (epub)
Clinical ResearchOncology (Medical)
Susumu Okano, Makoto Tahara, Kiyoaki Tsukahara et al.
✦ AI-curated · Sources linked
In 30 seconds
The phase II DISCOVARY trial evaluated darolutamide, both alone and with goserelin, in patients with androgen receptor-positive unresectable locally advanced or recurrent/metastatic salivary gland carcinoma. The combination therapy showed a confirmed objective response rate of 45.2% and a median progression-free survival of 13.1 months, compared to 8.3% and 5.7 months for monotherapy.
Key findings
- The combination of darolutamide and goserelin achieved an objective response rate of 45.2%.
- Monotherapy with darolutamide resulted in a confirmed objective response rate of 8.3%.
- Median progression-free survival was 13.1 months for the combination cohort versus 5.7 months for monotherapy.
- Twelve-month overall survival rates were 91.3% for the combination and 87.0% for monotherapy.
Why it matters
This study highlights a potential new treatment strategy for a rare and aggressive cancer with limited options. The combination therapy may offer improved outcomes while preserving quality of life.